Innovation Engine

DEVELOPING NEXT-GENERATION BISPECIFIC COMPOUNDS AND INNOVATIVE THERAPIES

Biohaven is developing drug candidates based on its proprietary, next-generation bispecific technology platforms and other innovative approaches. These bispecific platforms are modular in design to enable rapid generation of novel therapies for the treatment of diseases with high unmet medical needs. The other innovative therapies are comprised of novel approaches with potential to be first-in-class or best-in-class treatments.

ION CHANNEL

Kv7

Our Kv7 potassium channel platform supports the development of small molecule treatments within our portfolio. The Kv7 platform offers therapeutic opportunity in multiple disease states.

LEARN MORE
TRPM3

In addition to BHV-2100, we are optimizing other lead compounds for TRPM3-mediated disorders of the peripheral and central nervous systems.

LEARN MORE

DEGRADERS

MoDE

MoDE™ plaform is a proprietary drug development platform for small molecule therapies to address a broad range of antibody-mediated diseases.

LEARN MORE

NEXT-GEN ADCs

MATE

MATE™ platform is a proprietary drug development platform for the development of next-generation antibody conjugates that enables site-directed pairing with off-the-shelf therapeutic monoclonal antibodies (mAbs), or therapeutic commercial immunoglobulin (IG) pooled from donors.

LEARN MORE